Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Felbinac Trometamol Injection in Healthy Subjects
NCT03617510Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of felbinac in pain (4 arms), sponsored by Yiling Pharmaceutical. Primary endpoint: Tolerance evaluation index. Started Jul 2018; status: completed.
02
Drugs
felbinac
03
Conditions
pain
Beyond the preview
Go deeper on NCT03617510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617510.